Back HBV Treatment Experimental HBV Drugs

Experimental HBV Drugs

AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.


Read more:

AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response

Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. alt

Read more:

Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.

Read more:

Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine

Gilead Sciences and GlobeImmune announced this week that they will collaborate on the development and commercialization of a hepatitis B virus (HBV) therapeutic vaccine using GlobeImmune's Tarmogen yeast vector technology. In contrast to widely used HBV preventive vaccines, therapeutic vaccines are designed to stimulate the body's immune response to the virus, and may be used in conjunction with oral antiviral drugs. alt

Read more:

Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine

Dynavax Technologies announced this week that a Data Safety Monitoring Board has reviewed interim data from more than 2000 participants in 2 Phase 3 studies of the company's investigational hepatitis B vaccine, Hepislav, and determined that the trial may go forward without modification.

Read more: